Upstart Akero continues its swoosh into NASH space with $70M windfall round
Akero Therapeutics first swooshed onto the NASH stage with a drug in-licensed from Amgen, recruiting Gilead’s Andrew Cheng as CEO several months later and making …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
